MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) Short Interest Update

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) was the recipient of a large drop in short interest in the month of December. As of December 15th, there was short interest totaling 187,740 shares, a drop of 31.4% from the November 30th total of 273,552 shares. Based on an average trading volume of 194,579 shares, the short-interest ratio is presently 1.0 days. Approximately 0.5% of the company’s shares are sold short. Approximately 0.5% of the company’s shares are sold short. Based on an average trading volume of 194,579 shares, the short-interest ratio is presently 1.0 days.

MIRA Pharmaceuticals Trading Up 0.7%

Shares of NASDAQ:MIRA traded up $0.01 during midday trading on Tuesday, hitting $1.49. 124,079 shares of the company’s stock were exchanged, compared to its average volume of 250,072. MIRA Pharmaceuticals has a 12 month low of $0.73 and a 12 month high of $2.45. The stock has a 50 day moving average price of $1.49 and a 200-day moving average price of $1.44.

MIRA Pharmaceuticals (NASDAQ:MIRA) last released its quarterly earnings results on Thursday, November 13th. The company reported ($1.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($1.07). As a group, equities research analysts expect that MIRA Pharmaceuticals will post -0.6 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on MIRA shares. Weiss Ratings reissued a “sell (e+)” rating on shares of MIRA Pharmaceuticals in a research note on Monday. Wall Street Zen downgraded MIRA Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, November 22nd. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has an average rating of “Sell”.

Institutional Investors Weigh In On MIRA Pharmaceuticals

Several institutional investors have recently bought and sold shares of the stock. Two Sigma Investments LP lifted its stake in MIRA Pharmaceuticals by 129.8% during the 3rd quarter. Two Sigma Investments LP now owns 45,703 shares of the company’s stock valued at $62,000 after acquiring an additional 25,816 shares in the last quarter. First American Bank grew its stake in shares of MIRA Pharmaceuticals by 150.0% in the 3rd quarter. First American Bank now owns 50,000 shares of the company’s stock worth $68,000 after acquiring an additional 30,000 shares in the last quarter. XTX Topco Ltd bought a new stake in shares of MIRA Pharmaceuticals in the 2nd quarter worth $26,000. Creative Planning purchased a new stake in shares of MIRA Pharmaceuticals in the second quarter valued at about $27,000. Finally, International Assets Investment Management LLC bought a new position in shares of MIRA Pharmaceuticals during the second quarter valued at about $42,000. Institutional investors own 35.16% of the company’s stock.

MIRA Pharmaceuticals Company Profile

MIRA Pharmaceuticals, Inc operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.